Ricard Masia
Senior Director, Translational Medicine Crossbow Therapeutics
Dr. Ricard Masia is currently senior director of translational medicine at Crossbow Therapeutics, a clinical-stage biotechnology company developing TCR-mimetic T cell engagers for the treatment of hematologic and solid malignancies. His expertise is in designing translational strategies to advance immuno-oncology drug development, spanning discovery, IND-enabling stage, and early-stage clinical trials. Two areas of focus are the preclinical characterization of in vivo potency and safety of drug candidates, and the development and implementation of biomarker assays to support patient selection and pharmacodynamic monitoring in phase 1/2 trials. Prior to his work in industry, Dr. Masia was a physician-scientist and practicing academic pathologist at a major medical center, with a research focus on gastrointestinal and liver disease.
Seminars
- Rationale for Crossbow Therapeutics’ approach to TERT targeting and for CBX-663 design
- In vitro binding and in vitro potency against cancer cell lines, demonstrating superior potency of bivalent vs. monovalent format (2+1 vs 1+1)
- In vivo efficacy in mouse CDX models of AML and NSCLC, and in vitro and in vivo safety with focus on bone marrow progenitor cells
